scispace - formally typeset
Search or ask a question

Answers from top 10 papers

More filters
Papers (10)Insight
These results are consistent with the idea that psilocybin therapy revives emotional responsiveness on a neural and psychological level, which may be a key treatment mechanism for psychedelic therapy.
The present data do not provide support for this concern and are consistent with recently renewed clinical research suggesting possible therapeutic applications of psilocybin.
These data are consistent with animal studies and provide the first evidence in humans that psilocybin-induced psychosis is due to serotonin-2A receptor activation, independently of dopamine stimulation.
Overall, the results demonstrate that psilocybin-evoked synaptic rewiring in the cortex is fast and enduring, potentially providing a structural trace for long-term integration of experiences and lasting beneficial actions.
To many people brought up in the Reagan drug war era with the ‘drugs fry your brain’ message, psilocybin may seem a strange and possibly even a dangerous drug treatment of serious mental illness.
Psilocybin had no effect on low-level visually induced and motor-induced gamma-band oscillations, suggesting that some basic elements of oscillatory brain activity are relatively preserved during the psychedelic experience.
Evidence is also presented that the central nervous system effects of psilocybin are exerted only after its transformation to the 4-hydroxy analog, psilocin.
Our findings provide further evidence for the rapid plasticity-promoting effects of psilocybin.
These experiments indicate that possibly in the intact animal psilocybin is rapidly dephosphorylated and is pharmacologically active as psilocin, while the duration of the effect might be controlled by the oxidation of the latter compound to an o-quinone type of structure.
The results of this study demonstrate the rapid dephosphorylation of psilocybin by the intact mouse.

See what other people are reading

Are there benifits of using microdosing of psychedelics to treat psychiatric illness?
5 answers
Are there benifits of using microdosing of psychedelics to treat psychiatric illness?
5 answers
What is the link between pomegranate and NAFLD?
5 answers
Does taking DPP-4 inhibitors affect intestinal gas?
5 answers
How ALP and ALT act as biomarkers for metal toxicity in liver?
5 answers
How Palas et Al (2005) explain that ALP and ALT act as biomarkers for liver toxicity by metals?
5 answers
What is the current research on the use of psilocybin for treating depression?
5 answers
Current research on psilocybin for treating depression shows promising results. Studies indicate that psilocybin, when administered with psychological support, induces rapid improvement in depressive symptoms that can last for weeks. Mechanisms of psilocybin's antidepressant effects involve changes in serotonin or glutamate receptor activity, synaptogenesis, and alterations in brain connectivity and neurotransmission. Research highlights psilocybin's efficacy in treating tobacco addiction, anxiety, and depression related to life-threatening illnesses, with no serious adverse events reported. Psilocybin-assisted group therapy has shown effectiveness in relieving depression in cancer patients, with significant clinical response and remission rates observed over 18 months. Overall, the data supports further exploration of psilocybin as a novel and potentially effective treatment for depression, especially for treatment-resistant cases.
What are the species of ayahuasca?
5 answers
Ayahuasca, a psychedelic plant brew, is typically composed of two main species: Banisteriopsis caapi, the ayahuasca vine, and Psychotria viridis, the chacruna plant. The ayahuasca vine contains harmala alkaloids, acting as monoamine oxidase-A enzyme inhibitors, while the chacruna plant provides dimethyltryptamine (DMT), a potent psychedelic compound. These components work synergistically to induce visionary experiences and have been traditionally used by indigenous tribes in the Amazon for healing and spiritual purposes. Ayahuasca's pharmacological properties stem from the combination of these two species, with the vine's MAOI properties enhancing the effects of DMT found in the leaves, leading to its psychoactive and therapeutic potential.
What is the role of TNF alpha on beta thalassemia?
4 answers
TNF-alpha plays a significant role in beta thalassemia by influencing various aspects of the disease. Studies have shown that TNF-alpha gene polymorphisms are associated with differences in Vitamin D, Calcium, ALP, and ferritin levels in beta thalassemia patients. Additionally, TNF-alpha has been linked to ineffective erythropoiesis in thalassemic patients, affecting erythropoietin (EPO) and erythropoietin receptor (EPOR) expression, leading to reduced cell proliferation and increased apoptosis in erythroid progenitor cells. Elevated TNF-alpha levels in beta thalassemia patients have been observed, potentially contributing to complications like anemia and immune-mediated issues, with changes in TNF concentrations post-bone marrow transplantation correlating with immune complications.
Is assisted therapy with psychedelic efficace?
5 answers
Assisted therapy with psychedelics has shown promising efficacy in treating various mental health conditions. Studies have demonstrated positive outcomes in managing treatment-resistant cases, personality disorders, PTSD, major depression, and substance use disorders. Psychedelic agents like psilocybin, ayahuasca, LSD, and MDMA have been found to produce rapid and enduring improvements in anxiety, depression, and PTSD symptoms, with multiple dosing sessions showing greater efficacy. Additionally, psilocybin-assisted therapy has shown benefits in reducing heavy drinking days and promoting smoking abstinence in patients with substance use disorders. The use of psychedelic substances presents a novel approach that may offer significant advantages in the treatment of mental health conditions, warranting further research and exploration in this field.
Is assisted therapy with psilocybin efficace?
5 answers
Assisted therapy with psilocybin has shown promising efficacy in treating various mental health conditions. Studies have demonstrated that psilocybin-assisted psychotherapy (PAP) can be effective in managing treatment-resistant depression, especially in cases of difficult-to-treat depression and depression in cancer patients. The use of psilocybin coupled with group therapy has shown significant improvements in depressive symptoms, with high response and remission rates observed. Additionally, PAP has been found to be cost-effective compared to conventional medication and cognitive behavioral therapy for severe depression, further supporting its efficacy. Combining psilocybin with psychological support has shown long-term effectiveness in reducing depression and anxiety severity, indicating its potential as a valuable therapeutic option.